Rove Hotels Unveils the Only On-Site Hotel at Expo 2020 Dubai
27.10.2020 13:17:00 EET | Business Wire | Press release
With Expo 2020 Dubai now less than a year away, the eyes of the world are back on this much-awaited event, as it gears up to help shape the future. A homegrown hotel brand that can be found at the heart of communities across Dubai – Rove Hotels made the very special announcement that it will be the only hotel at Expo 2020 Dubai, which will be taking place from 1st October 2021 to 31st March 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005569/en/
For those who Rove: Rove Expo 2020, the only on-site hotel at Expo 2020 Dubai, adjacent to Al Wasl Plaza - (Photo : AETOSWire)
A gateway to inspiring experiences of culture, innovation and human excellence at Expo 2020, the Rove Expo 2020 hotel – part of the Rove brand – will feature 312 king, twin and accessible Rover Rooms, as well as 19 Rover suites. Furthermore, the only hotel at Expo 2020 will boast several F&B outlets, including The Daily, a grab & go Rove Café and The Bar, along with a rooftop swimming pool and sundeck overlooking the Al Wasl Plaza, 100% sustainable in-room amenities, a 24-hour gym, prayer rooms, and more.
Marjan Faraidooni, Chief Pavilions and Exhibitions Officer at Expo 2020 Dubai, said, “This is a significant step forward in the development of the Expo 2020 site. An on-site hotel is a great addition to the world-class facilities we are creating to welcome people from all around the world to experience this once-in-a-lifetime event.”
“Rove Expo 2020 will remain as a permanent modern hospitality offering at District 2020, which will evolve into a smart human-centric community as the future of Expo 2020 Dubai. It will support District 2020’s aim to create a mixed-use development and an innovation-driven urban destination that caters to the needs of its future workers, residents and visitors through its diverse community offering,” she added.
The Rove team is even more excited and determined than ever to cater to the diverse needs of visitors from all over the world as the one and only hotel destination inside Expo 2020.
“This exciting hotel will no doubt boost the already huge appeal of such a historical and major event for the UAE, and offer Expo 2020 visitors a new and innovative type of hospitality option at the heart of the Expo site,” said Mr. Ahmad Thani Rashed Al Matrooshi, Board Director of Rove Hotels LLC.
For more information, visit https://www.rovehotels.com/hotel/rove-expo-2020/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005569/en/
Contact information
Katch International
Dhara Bhatia,
Engagement Consultant, +971567944126
dhara@katchthis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom